News Releases

Date	Title	Additional Formats
November 8, 2022	Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 3, 2022	Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
November 1, 2022	Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
October 24, 2022	Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
October 23, 2022	Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
October 18, 2022	Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
September 26, 2022	Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
September 7, 2022	Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 2, 2022	Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates
June 1, 2022	Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference